Vesalius Therapeutics focuses on developing innovative approaches to treat common diseases, utilizing proprietary patient-derived models to screen drug candidates and identify new therapeutic targets.

Vesalius Therapeutics

Vesalius Therapeutics | 2,231 followers on LinkedIn. Pioneering a revolutionary platform to generate breakthrough treatments for common diseases | Pioneering a revolutionary platform to generate breakthrough treatments for common diseases.

Data Solutions Architect

Nick B.

Senior Vice President and Head of Drug Discovery at Vesalius Therapeutics (formerly Serqet Therapeutics)

Ben Munoz

Talita Turnier

SVP Platform Development, Vesalius Therapeutics | Research leader | Platform development and operation | Data science | Target discovery/validation |…

Chris Cotsapas

Vesalius and GSK share the conviction that targeting the causal factors of common diseases like Parkinson’s disease is the key to developing breakthrough medicines faster and with a higher probability of success. Read more: https://lnkd.in/eSZmP-Vz #ParkinsonsDisease #ParkinsonsAwareness #Biotech #Parkinsons

Exciting news from Flagship Pioneering as they announce the raise of $3.6 billion to fuel breakthrough innovations that transform human health and sustainability. We are proud to be #FlagshipFounded and part of an ecosystem of companies – present and future – taking bold scientific leaps to deliver a better future for all. https://lnkd.in/epadgTVp

Our CEO Christopher Austin describes how Vesalius has developed the first precision platform for common diseases and what’s ahead for the company as its lead candidates approach the clinic.

Our CEO Christopher Austin had a great discussion last week with colleagues at the Flagship Pioneering studio on the opportunities for bioplatforms to dramatically scale the creation of new medicines while also finding novel ways to treat common diseases with a level of precision that was previously reserved for rare diseases. #JPM2024

In Flagship’s 2024 Annual Letter, founder and CEO @Noubar Afeyan reflects on navigating through polycrisis and what it will take to make bigger leaps for patients and the planet including {novel partnerships, continuous innovation, global reach, both forms of AI} Read his annual newsletter here: https://lnkd.in/ez-KuWxi #FlagshipFounded

Metric
Company Name	Vesalius Therapeutics
Symbol
MSH ID	COM:VESALIUSTX
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count
Website	vesaliustx.com
LinkedIn	vesaliustx
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

VESA

COM:VESALIUSTX

Vesalius Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue